Journal article

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression

ME Montanez-Wiscovich, DD Seachrist, MD Landis, J Visvader, B Andersen, RA Keri

ONCOGENE | NATURE PUBLISHING GROUP | Published : 2009

Abstract

ErbB2/HER2/Neu-overexpressing breast cancers are characterized by poor survival due to high proliferation and metastasis rates and identifying downstream targets of ErbB2 should facilitate developing novel therapies for this disease. Gene expression profiling revealed the transcriptional regulator LIM-only protein 4 (LMO4) is upregulated during ErbB2-induced mouse mammary gland tumorigenesis. Although LMO4 is frequently overexpressed in breast cancer and LMO4-overexpressing mice develop mammary epithelial tumors, the mechanisms involved are unknown. In this study, we report that LMO4 is a downstream target of ErbB2 and PI3K in ErbB2-dependent breast cancer cells. Furthermore, LMO4 silencing ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by CURE


Awarded by NIH


Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES


Awarded by NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES


Funding Acknowledgements

We thank Jonathan Mosley for help with statistical analyses, Meredith Sorenson for technical support and members of the Keri laboratory, especially Gina Bernardo and Emhonta Johnson, for useful discussions. We are grateful for assistance from the Case Comprehensive Cancer Center core facilities (P30 CA43703). This work was supported by: RO1-CA090398 (RAK), CURE supplementary grant to RO1-CA090398 (RAK), NIH AR44882 (BA), T32-GM007250 (MEMW) and F31-CA123642 (MEMW).